Equality and Human Rights Consultation - NICE TA - Trastuzumab Emtansine for Treating HER2 Positive Advanced Breast Cancer after Trastuzumab and a Taxane (Review of TA371)

Consultation opened on 15 June 2017. Closing date 26 July 2017.

Summary

NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the Department established links with NICE whereby all technology appraisals and clinical guidelines published from that date are locally reviewed for applicability to Northern Ireland and, where appropriate, are endorsed for implementation in health and social care. THE LOCAL REVIEW DOES NOT REASSESS THE CLINICAL AND COST EVIDENCE USED BY NICE IN FORMING ITS ADVICE. This link has ensured that Northern Ireland has access to up-to-date, independent, professional, evidence-based guidance on the value of health care interventions.

Documents

Consultation description

Guidance for the consultation can be found on the NICE website.

The HSC (SQSD) 2/13 circular provides details of the process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.

In order to meet the timescales set out in the circular, the closing date for responses is Wednesday 26th July 2017.

This will inform the Equality Screening.

Share this consultation

Back to top